Is Smith & Nephew plc (SNN) a Buy, Sell, or Hold?
NYSE : SNN
Smith & Nephew plc
$30.11 USD
$0.42 (1.41%)
- Volume
- 1.44M
- Average Volume
- 1.79M
- Market Capitalization
- $12.64B
- P/E Ratio
- 19.76
- Dividend Yield
- 2.61%
- Price Target
- $30.93
- Year High
- $38.79
- Year Low
- $28.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.52
- Current Ratio
- $2.14
Company Overview
NYSE
Deepak S Nath
Medical - Devices
Healthcare
SNN
18362
GB
USD
Liquidity Metrics
0.73
2.14
1.11
0.37
0.52
Sales & Valuation
$6.16B
1.98
2.45
14.88
2.00
Profitability
$1.44
$625M
10.08%
12.65%
12.25%
5.81%
P/E Metrics
19.76
0.59
0.59
Analyst Price Target & Rating
$30.93
$31.85
$30.00
3/5
23 Analysts
-2.64%
Financial Health Scores
4.24
7/9
$2.51B
$10.46B
$5.17B
$1.76B
Key Metrics (TTM)
$15.58B
2.44
9.40
2.14
12.25%
8.85%
5.07%
6.76%
$10.22
244 days
Company Executives
| Name | Title |
|---|---|
| Vasant Padmanabhan | President Research & Development, ENT and Emerging Markets |
| Emily Heaven | Head of Investor Relations |
| John Terence Rogers | Chief Financial Officer & Executive Director |
| Alison Parkes | Chief Compliance Officer & Compliance APAC |
| Elga Lohler | Chief Human Resources Officer |
| Helen Barraclough | Group General Counsel & Company Secretary |
| Deepak S. Nath | Chief Executive Officer & Director |
| Ajay Dhankhar | Chief Corporate Development & Strategy Officer |
| Paul Connolly | President of Global Operations |
| Charles Reynolds | Head of Corporate Communication |
Poll Results
No votes yet today — be the first to share your view!
About Smith & Nephew plc (NYSE:SNN) Stock
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative ... conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
2026-08-05 13:00:00
Canton, Ohio—As thousands of football fans descend on Canton for the 2026 Pro Football Hall of Fame Enshrinement Week, Smith+Nephew, the Global medical technology company, will join the celebration with a series of engagement activities highlighting the connection between movement, recovery and the enduring spirit of the game. Smith+Nephew is the official Joint Replacement and Sports Medicine Technology Partner of the Pro Football Hall of Fame.
Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript
2026-08-04 15:00:01
Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript
Smith & Nephew cuts sales outlook after weak US trading
2026-08-04 03:09:12
Smith & Nephew PLC (LSE:SN) has cut its full-year revenue growth forecast after weakness in its US orthopaedics and wound care businesses in the second quarter. The FTSE 100 medical technology group now expects annual revenue growth of around 4%, down from its previous forecast of around 6%.
Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Recommendation of “Hold” from Brokerages
2026-08-03 04:16:04
Shares of Smith and Nephew SNATS, Inc. (NYSE: SNN - Get Free Report) have received a consensus rating of "Hold" from the six brokerages that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month
Smith+Nephew Expands ASC Platform to Support Value-Based Care
2026-07-23 14:30:37
SNN expands ASC Solutions with an integrated platform, analytics and partners to boost efficiency, growth and patient outcomes in outpatient care.
Smith+Nephew Launches LYNX COBLATION Wand for ENT Airway Surgery
2026-07-16 12:46:08
SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.
2026-07-09 02:00:00
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
2026-07-09 02:00:00
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of surgery Die Chirurgie, the new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
Frequently Asked Questions
-
What is the current Smith & Nephew plc (SNN) stock price?
-
Smith & Nephew plc(NYSE:SNN) stock price is $30.11 in the last trading session. During the trading session, SNN stock reached the peak price of $38.79 while $28.56 was the lowest point it dropped to. The percentage change in SNN stock occurred in the recent session was 1.41% while the dollar amount for the price change in SNN stock was $0.42.
-
SNN's industry and sector of operation?
-
The NYSE listed SNN is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of SNN?
-
Vasant Padmanabhan | President Research & Development, ENT and Emerging Markets
Emily Heaven | Head of Investor Relations
John Terence Rogers | Chief Financial Officer & Executive Director
Alison Parkes | Chief Compliance Officer & Compliance APAC
Elga Lohler | Chief Human Resources Officer -
How many employees does SNN have?
-
Number of SNN employees currently stands at 18362. SNN operates from Building 5 Croxley Park Hatters Lane, Watford, HRT WD18 8YE, GB.
-
Link for SNN official website?
-
Official Website of SNN is: https://www.smith-nephew.com
-
How do I contact SNN?
-
SNN could be contacted at phone #44 1923 477 100 and can also be accessed through its website. SNN operates from Building 5 Croxley Park Hatters Lane, Watford, HRT WD18 8YE, GB.
-
How many shares of SNN are traded daily?
-
The average number of SNN shares traded daily for last 3 months was 1.79M.
-
What is the market cap of SNN currently?
-
The market value of SNN currently stands at $12.64B with its latest stock price at $30.11